"10.1371_journal.pmed.1001718","plos medicine","2014-09-09T00:00:00Z","Andrew Boulle; Michael Schomaker; Margaret T May; Robert S Hogg; Bryan E Shepherd; Susana Monge; Olivia Keiser; Fiona C Lampe; Janet Giddy; James Ndirangu; Daniela Garone; Matthew Fox; Suzanne M Ingle; Peter Reiss; Francois Dabis; Dominique Costagliola; Antonella Castagna; Kathrin Ehren; Colin Campbell; M John Gill; Michael Saag; Amy C Justice; Jodie Guest; Heidi M Crane; Matthias Egger; Jonathan A C Sterne","Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Department of Health, Provincial Government of the Western Cape, Cape Town, South Africa; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain; University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland; Research Department of Infection and Population Health, UCL Medical School, London, United Kingdom; McCord Hospital, Durban, South Africa; Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa; Médecins Sans Frontières, Khayelitsha, South Africa; Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America; Stichting HIV Monitoring, Amsterdam, The Netherlands; Department of Global Health and Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, and Amsterdam Institute for Global health and Development, Amsterdam, the Netherlands; INSERM, Centre INSERM U897 Epidémiologie et Biostatistique, Bordeaux, France; Université Bordeaux, Institut de Santé Publique Epidémiologie Développement (ISPED), Bordeaux, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis dEpidémiologie et de Santé Publique, Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis dEpidémiologie et de Santé Publique, Paris, France; Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy; First Department of Internal Medicine, University Hospital of Cologne, Germany; Centre dEstudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Institut català dOncologia (ICO), Agència Salut Pública de Catalunya (ASPC), Generalitat de Catalunya, Badalona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Division of Infectious Diseases, University of Calgary, Calgary, Canada; Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, Alabama, United States of America; Yale University School of Medicine, New Haven, Connecticut, United States of America; VA Connecticut Healthcare System, West Haven, Connecticut, United States of America; HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, Georgia, United States of America; Center for AIDS Research, University of Washington, Seattle, Washington, United States of America","Conceived and designed the experiments: AB MS MTM RSH BES SM OK FL JG JN DG MF SMI PR FD DC AC KE CC MJG MS ACJ JG HMC ME JACS. Analyzed the data: MS AB MM JACS. Wrote the first draft of the manuscript: AB. Contributed to the writing of the manuscript: MS MTM RSH BES SM OK FL JG JN DG MF SMI PR FD DC AC KE CC MJG MS ACJ JG HMC ME JACS. ICMJE criteria for authorship read and met: AB MS MTM RSH BES SM OK FL JG JN DG MF SMI PR FD DC AC KE CC MJG MS ACJ JG HMC ME JACS. Agree with manuscript results and conclusions: AB MS MTM RSH BES SM OK FL JG JN DG MF SMI PR FD DC AC KE CC MJG MS ACJ JG HMC ME JACS.","MSS is the local principal investigator on studies sponsored by Abbvie, Gilead, BMS, Merck, BI, ViiV, and Jannsen, where funding goes directly to the institution but not to MSS. PR, through his institution, has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceutica N.V., Merck&Co, Bristol-Myers Squibb, and ViiV Healthcare, and travel support through his institution from Gilead Sciences and Janssen Pharmaceutica N.V. In addition, PR has served on a scientific advisory board for Gilead Sciences and serves on a data safety monitoring committee for Janssen Pharmaceutica N.V., for which his institution has received remuneration. KE has received honoraria from Abbott for educational lectures. JS has received research grants from the UK Medical Research Council. JS has received payment from Gilead Sciences, Inc for educational presentations.","2014","09","Andrew Boulle","AB",26,TRUE,24,NA,4,1,TRUE,TRUE,FALSE,0,NA,FALSE
